Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx

Werner Garavello, Gabriella Nicolini, Alessia Aguzzi, Daniele Maggioni, Biagio Eugenio Leone, Paola Viganò, Renato Maria Gaini, Giovanni Tredici

Research output: Contribution to journalArticle

Abstract

Mitogen-activated protein kinase (MAPK) cascades transmit and amplify signals involved in cell proliferation as well as in cell death. In this study, the potential derangement of MAPK pathways has been evaluated in human squamous cell carcinomas (SCC) of the larynx. The expression and activity of the MAPK p38, ERK1/2p44/p42 and JNK/SAPKp46/p54 have been investigated by immunoblot analysis of tissue homogenates in 27 samples of primary laryngeal cancer and in 27 paired non-neoplastic laryngeal mucosa. On the same tissues, the activation of MAPK JNK/SAPKp46/p54 was also analyzed by an ELISA assay. The results obtained showed that both total and phosphorylated levels of JNK/SAPKp46/p54 and p38 were not different between tumor and normal samples. Conversely, while total protein levels for both ERK1p44 and ERK2p42 were not statistically different between tumor and normal samples, the analysis of the level of the activated forms of ERK1/2 showed a statistically significant decreased phosphorylation of both isoforms in the tumor samples compared to the control tissues. The rate of reduction was similar for both isoforms. Immunohistochemical analysis of all the activated MAPK (p38, JNK/SAPKp46/ p54 and ERK1/2p44/p42) in both laryngeal SCC and normal mucosa demonstrated no difference of cellular localization. Activated ERK1/2p44/p42 and activated p38 demonstrated a nucleo-cytoplasmic distribution whereas activated JNK/SAPKp46/p54 were localized into the cytoplasmic membrane. The decreased activity of ERK1/2p44/42 in laryngeal SCC might reflect alterations in tumor suppressing activity or might derive from the interplay among various transduction pathways.

Original languageEnglish
Pages (from-to)479-484
Number of pages6
JournalOncology Reports
Volume16
Issue number3
Publication statusPublished - Sep 2006

Fingerprint

Extracellular Signal-Regulated MAP Kinases
Larynx
Protein Kinases
Squamous Cell Carcinoma
Phosphorylation
p38 Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinases
Neoplasms
Protein Isoforms
Laryngeal Mucosa
Laryngeal Neoplasms
JNK Mitogen-Activated Protein Kinases
Mucous Membrane
Cell Death
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Cell Membrane
Proteins

Keywords

  • Laryngeal cancer
  • Mitogen-activated protein kinases
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Garavello, W., Nicolini, G., Aguzzi, A., Maggioni, D., Leone, B. E., Viganò, P., ... Tredici, G. (2006). Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx. Oncology Reports, 16(3), 479-484.

Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx. / Garavello, Werner; Nicolini, Gabriella; Aguzzi, Alessia; Maggioni, Daniele; Leone, Biagio Eugenio; Viganò, Paola; Gaini, Renato Maria; Tredici, Giovanni.

In: Oncology Reports, Vol. 16, No. 3, 09.2006, p. 479-484.

Research output: Contribution to journalArticle

Garavello, W, Nicolini, G, Aguzzi, A, Maggioni, D, Leone, BE, Viganò, P, Gaini, RM & Tredici, G 2006, 'Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx', Oncology Reports, vol. 16, no. 3, pp. 479-484.
Garavello, Werner ; Nicolini, Gabriella ; Aguzzi, Alessia ; Maggioni, Daniele ; Leone, Biagio Eugenio ; Viganò, Paola ; Gaini, Renato Maria ; Tredici, Giovanni. / Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx. In: Oncology Reports. 2006 ; Vol. 16, No. 3. pp. 479-484.
@article{170d28c4b74143659c3a03f5b1f945be,
title = "Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx",
abstract = "Mitogen-activated protein kinase (MAPK) cascades transmit and amplify signals involved in cell proliferation as well as in cell death. In this study, the potential derangement of MAPK pathways has been evaluated in human squamous cell carcinomas (SCC) of the larynx. The expression and activity of the MAPK p38, ERK1/2p44/p42 and JNK/SAPKp46/p54 have been investigated by immunoblot analysis of tissue homogenates in 27 samples of primary laryngeal cancer and in 27 paired non-neoplastic laryngeal mucosa. On the same tissues, the activation of MAPK JNK/SAPKp46/p54 was also analyzed by an ELISA assay. The results obtained showed that both total and phosphorylated levels of JNK/SAPKp46/p54 and p38 were not different between tumor and normal samples. Conversely, while total protein levels for both ERK1p44 and ERK2p42 were not statistically different between tumor and normal samples, the analysis of the level of the activated forms of ERK1/2 showed a statistically significant decreased phosphorylation of both isoforms in the tumor samples compared to the control tissues. The rate of reduction was similar for both isoforms. Immunohistochemical analysis of all the activated MAPK (p38, JNK/SAPKp46/ p54 and ERK1/2p44/p42) in both laryngeal SCC and normal mucosa demonstrated no difference of cellular localization. Activated ERK1/2p44/p42 and activated p38 demonstrated a nucleo-cytoplasmic distribution whereas activated JNK/SAPKp46/p54 were localized into the cytoplasmic membrane. The decreased activity of ERK1/2p44/42 in laryngeal SCC might reflect alterations in tumor suppressing activity or might derive from the interplay among various transduction pathways.",
keywords = "Laryngeal cancer, Mitogen-activated protein kinases, Squamous cell carcinoma",
author = "Werner Garavello and Gabriella Nicolini and Alessia Aguzzi and Daniele Maggioni and Leone, {Biagio Eugenio} and Paola Vigan{\`o} and Gaini, {Renato Maria} and Giovanni Tredici",
year = "2006",
month = "9",
language = "English",
volume = "16",
pages = "479--484",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx

AU - Garavello, Werner

AU - Nicolini, Gabriella

AU - Aguzzi, Alessia

AU - Maggioni, Daniele

AU - Leone, Biagio Eugenio

AU - Viganò, Paola

AU - Gaini, Renato Maria

AU - Tredici, Giovanni

PY - 2006/9

Y1 - 2006/9

N2 - Mitogen-activated protein kinase (MAPK) cascades transmit and amplify signals involved in cell proliferation as well as in cell death. In this study, the potential derangement of MAPK pathways has been evaluated in human squamous cell carcinomas (SCC) of the larynx. The expression and activity of the MAPK p38, ERK1/2p44/p42 and JNK/SAPKp46/p54 have been investigated by immunoblot analysis of tissue homogenates in 27 samples of primary laryngeal cancer and in 27 paired non-neoplastic laryngeal mucosa. On the same tissues, the activation of MAPK JNK/SAPKp46/p54 was also analyzed by an ELISA assay. The results obtained showed that both total and phosphorylated levels of JNK/SAPKp46/p54 and p38 were not different between tumor and normal samples. Conversely, while total protein levels for both ERK1p44 and ERK2p42 were not statistically different between tumor and normal samples, the analysis of the level of the activated forms of ERK1/2 showed a statistically significant decreased phosphorylation of both isoforms in the tumor samples compared to the control tissues. The rate of reduction was similar for both isoforms. Immunohistochemical analysis of all the activated MAPK (p38, JNK/SAPKp46/ p54 and ERK1/2p44/p42) in both laryngeal SCC and normal mucosa demonstrated no difference of cellular localization. Activated ERK1/2p44/p42 and activated p38 demonstrated a nucleo-cytoplasmic distribution whereas activated JNK/SAPKp46/p54 were localized into the cytoplasmic membrane. The decreased activity of ERK1/2p44/42 in laryngeal SCC might reflect alterations in tumor suppressing activity or might derive from the interplay among various transduction pathways.

AB - Mitogen-activated protein kinase (MAPK) cascades transmit and amplify signals involved in cell proliferation as well as in cell death. In this study, the potential derangement of MAPK pathways has been evaluated in human squamous cell carcinomas (SCC) of the larynx. The expression and activity of the MAPK p38, ERK1/2p44/p42 and JNK/SAPKp46/p54 have been investigated by immunoblot analysis of tissue homogenates in 27 samples of primary laryngeal cancer and in 27 paired non-neoplastic laryngeal mucosa. On the same tissues, the activation of MAPK JNK/SAPKp46/p54 was also analyzed by an ELISA assay. The results obtained showed that both total and phosphorylated levels of JNK/SAPKp46/p54 and p38 were not different between tumor and normal samples. Conversely, while total protein levels for both ERK1p44 and ERK2p42 were not statistically different between tumor and normal samples, the analysis of the level of the activated forms of ERK1/2 showed a statistically significant decreased phosphorylation of both isoforms in the tumor samples compared to the control tissues. The rate of reduction was similar for both isoforms. Immunohistochemical analysis of all the activated MAPK (p38, JNK/SAPKp46/ p54 and ERK1/2p44/p42) in both laryngeal SCC and normal mucosa demonstrated no difference of cellular localization. Activated ERK1/2p44/p42 and activated p38 demonstrated a nucleo-cytoplasmic distribution whereas activated JNK/SAPKp46/p54 were localized into the cytoplasmic membrane. The decreased activity of ERK1/2p44/42 in laryngeal SCC might reflect alterations in tumor suppressing activity or might derive from the interplay among various transduction pathways.

KW - Laryngeal cancer

KW - Mitogen-activated protein kinases

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33749175395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749175395&partnerID=8YFLogxK

M3 - Article

C2 - 16865246

AN - SCOPUS:33749175395

VL - 16

SP - 479

EP - 484

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -